ACRS Aclaris Therapeutics Inc

USD 1.19 0.00 0
Icon

Aclaris Therapeutics Inc (ACRS) Stock Analysis and Price Targets

COMMON STOCK | Diagnostics & Research | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.19

0.00 (0.00)%

USD 0.08B

0.45M

N/A

USD 15.67 (+1216.81%)

Icon

ACRS

Aclaris Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 1.19
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.08B

USD 15.67 (+1216.81%)

USD 1.19

Aclaris Therapeutics Inc (ACRS) Stock Forecast

N/A

Based on the Aclaris Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Aclaris Therapeutics Inc is not available over the next 12 months. Aclaris Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aclaris Therapeutics Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Aclaris Therapeutics Inc’s stock price was USD 1.19. Aclaris Therapeutics Inc’s stock price has changed by +1.71% over the past week, -4.03% over the past month and -85.45% over the last year.

No recent analyst target price found for Aclaris Therapeutics Inc
No recent average analyst rating found for Aclaris Therapeutics Inc

Company Overview Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segmen...Read More

https://www.aclaristx.com

640 Lee Road, Wayne, PA, United States, 19087

86

December

USD

USA

Adjusted Closing Price for Aclaris Therapeutics Inc (ACRS)

Loading...

Unadjusted Closing Price for Aclaris Therapeutics Inc (ACRS)

Loading...

Share Trading Volume for Aclaris Therapeutics Inc Shares

Loading...

Compare Performance of Aclaris Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ACRS

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Aclaris Therapeutics Inc (Sector: Diagnostics & Research )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
IDXX
IDEXX Laboratories Inc 0.00 (0.00%) USD43.04B 50.50 34.46

ETFs Containing ACRS

Symbol Name ACRS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Aclaris Therapeutics Inc (ACRS) Stock

Stock Target Advisor's fundamental analysis for Aclaris Therapeutics Inc's stock is Neutral.

Unfortunately we do not have enough data on ACRS's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ACRS's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on ACRS's stock to indicate if its overvalued.

The last closing price of ACRS's stock was USD 1.19.

The most recent market capitalization for ACRS is USD 0.08B.

Unfortunately we do not have enough analyst data on ACRS's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Aclaris Therapeutics Inc's stock.

As per our most recent records Aclaris Therapeutics Inc has 86 Employees.

Aclaris Therapeutics Inc's registered address is 640 Lee Road, Wayne, PA, United States, 19087. You can get more information about it from Aclaris Therapeutics Inc's website at https://www.aclaristx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...